AI Portfolio Summary
In 2025 Q4, GREAT POINT PARTNERS LLC maintained a portfolio of 42 distinct positions. The most significant new addition to the portfolio was DISC MEDICINE INC, which now represents 6.44% of the total fund value. They heavily accumulated shares in APOGEE THERAPEUTICS , increasing their position by 23.0%. Conversely, GREAT POINT PARTNERS LLC completely exited their position in ASCENDIS PHARMA A/S .
Total Positions
42
Quarter
2025 Q4
Top Holding
APGE (9.2%)
Top 10 Concentration
62.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-25 of 42
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
APGE
APOGEE THERAPEU...
|
Healthcare | 9.15% | 4.98% |
#1
7
Prev: #8
|
5.7 | 70,000 | 23.0% |
P
S
|
374,000 | $28,229,520 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AMLX
AMYLYX PHARMACE...
|
Healthcare | 6.85% | 9.53% |
#2
1
Prev: #1
|
4.8 | 50,000 | 2.9% |
P
S
|
1,750,000 | $21,140,000 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ZURA
ZURA BIO LTD
|
Healthcare | 6.48% | 6.81% |
#3
1
Prev: #4
|
2.6 | no change | no change |
P
S
|
3,815,930 | $19,995,473 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IRON
DISC MEDICINE I...
|
Healthcare | 6.44% | — |
#4
Prev: #—
|
4.6 | 250,000 | no change |
NEW
|
250,000 | $19,852,500 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RAPT
RAPT THERAPEUTI...
|
Healthcare | 6.38% | — |
#5
Prev: #—
|
4.6 | 581,187 | no change |
NEW
|
581,187 | $19,684,804 | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMVT
IMMUNOVANT INC
|
Healthcare | 6.18% | 3.32% |
#6
5
Prev: #11
|
4.6 | 250,000 | 50.0% |
P
S
|
750,000 | $19,065,000 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SLNO
SOLENO THERAPEU...
|
Healthcare | 6.00% | 6.27% |
#7
2
Prev: #5
|
4.6 | 175,000 | 77.8% |
P
S
|
400,000 | $18,520,000 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VOR
VOR BIOPHARMA I...
|
Healthcare | 5.81% | — |
#8
Prev: #—
|
4.3 | 1,370,107 | no change |
NEW
|
1,370,107 | $17,921,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DNTH
DIANTHUS THERAP...
|
Healthcare | 4.68% | 4.31% |
#9
Prev: #9
|
4.0 | 84,197 | 31.7% |
P
S
|
350,000 | $14,423,500 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
JBIO
JADE BIOSCIENCE...
|
Healthcare | 4.03% | 2.25% |
#10
6
Prev: #16
|
3.7 | 173,674 | 27.5% |
P
S
|
806,273 | $12,440,792 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KALV
KALVISTA PHARMA...
|
Healthcare | 3.59% | — |
#11
Prev: #—
|
3.4 | 685,632 | no change |
NEW
|
685,632 | $11,072,957 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CTNM
CONTINEUM THERA...
|
Healthcare | 2.96% | — |
#12
Prev: #—
|
3.2 | 800,000 | no change |
NEW
|
800,000 | $9,144,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EPRX
EUPRAXIA PHARMA...
|
Healthcare | 2.94% | 2.92% |
#13
1
Prev: #14
|
1.2 | no change | no change |
P
S
|
1,200,000 | $9,060,000 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
FULC
FULCRUM THERAPE...
|
Healthcare | 2.93% | — |
#14
Prev: #—
|
3.2 | 800,000 | no change |
NEW
|
800,000 | $9,048,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NKTR
NEKTAR THERAPEU...
|
Healthcare | 2.89% | 7.04% |
#15
12
Prev: #3
|
1.2 | -89,268 | -29.8% |
P
S
|
210,732 | $8,909,749 | 2019 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
UPB
UPSTREAM BIO IN...
|
Healthcare | 2.64% | 2.33% |
#16
1
Prev: #15
|
1.1 | no change | no change |
P
S
|
300,000 | $8,145,000 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NGNE
NEUROGENE INC
|
Healthcare | 2.34% | 3.19% |
#17
4
Prev: #13
|
1.0 | -96,814 | -21.7% |
P
S
|
350,000 | $7,210,000 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RARE
ULTRAGENYX PHAR...
|
Healthcare | 2.24% | — |
#18
Prev: #—
|
2.9 | 300,000 | no change |
NEW
|
300,000 | $6,900,000 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CNTX
CONTEXT THERAPE...
|
Healthcare | 2.23% | 1.87% |
#19
1
Prev: #20
|
0.9 | no change | no change |
P
S
|
4,683,711 | $6,885,055 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CGEM
CULLINAN THERAP...
|
Healthcare | 2.13% | — |
#20
Prev: #—
|
2.9 | 634,032 | no change |
NEW
|
634,032 | $6,562,231 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EVMN
EVOMMUNE INC
|
Healthcare | 1.80% | — |
#21
Prev: #—
|
2.7 | 325,000 | no change |
NEW
|
325,000 | $5,564,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ORKA
ORUKA THERAPEUT...
|
Healthcare | 1.80% | 1.45% |
#22
2
Prev: #24
|
0.7 | no change | no change |
P
S
|
183,330 | $5,556,732 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SLN
SILENCE THERAPE...
|
Healthcare | 1.59% | — |
#23
Prev: #—
|
2.6 | 808,032 | no change |
NEW
|
808,032 | $4,912,835 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
UNCY
UNICYCIVE THERA...
|
Healthcare | 1.49% | 1.43% |
#24
1
Prev: #25
|
0.6 | no change | no change |
P
S
|
796,558 | $4,596,140 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CLYM
CLIMB BIO INC
|
Healthcare | 1.27% | — |
#25
Prev: #—
|
2.5 | 979,534 | no change |
NEW
|
979,534 | $3,918,136 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ASND
ASCENDIS PHARMA...
|
Healthcare | 0.00% | 6.15% |
Sold All 😨
(Was: #6) |
0.3 | -75,000 | -100.0% |
CLOSED
|
— | $— | 2015 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABVX
ABIVAX SA SPONS...
|
Healthcare | 0.00% | 5.25% |
Sold All 😨
(Was: #7) |
0.3 | -150,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CYTK
CYTOKINETICS IN...
|
Healthcare | 0.00% | 3.40% |
Sold All 😨
(Was: #10) |
0.3 | -150,000 | -100.0% |
CLOSED
|
— | $— | 2014 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XENE
XENON PHARMACEU...
|
Healthcare | 0.00% | 3.31% |
Sold All 😨
(Was: #12) |
0.3 | -200,000 | -100.0% |
CLOSED
|
— | $— | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IONS
IONIS PHARMACEU...
|
Healthcare | 0.00% | 2.16% |
Sold All 😨
(Was: #17) |
0.3 | -80,000 | -100.0% |
CLOSED
|
— | $— | 2019 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AKRO
AKERO THERAPEUT...
|
Healthcare | 0.00% | 2.03% |
Sold All 😨
(Was: #18) |
0.3 | -103,848 | -100.0% |
CLOSED
|
— | $— | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TSHA
TAYSHA GENE THE...
|
Healthcare | 0.00% | 2.02% |
Sold All 😨
(Was: #19) |
0.3 | -1,500,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DBVT
DBV TECHNOLOGIE...
|
Healthcare | 0.00% | 1.56% |
Sold All 😨
(Was: #22) |
0.3 | -378,594 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LEGN
LEGEND BIOTECH ...
|
Healthcare | 0.00% | 1.53% |
Sold All 😨
(Was: #23) |
0.3 | -113,460 | -100.0% |
CLOSED
|
— | $— | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABSI
ABSCI CORPORATI...
|
Healthcare | 0.00% | 1.00% |
Sold All 😨
(Was: #27) |
0.3 | -796,438 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
HRMY
CALL
HRMY 10/17/2025...
|
CALL Option | 0.00% | 0.97% |
Sold All 😨
(Was: #28) |
0.3 | -85,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PLRX
PLIANT THERAPEU...
|
Healthcare | 0.00% | 0.52% |
Sold All 😨
(Was: #29) |
0.3 | -850,000 | -100.0% |
CLOSED
|
— | $— | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CAPR
PUT
CAPR 12/19/2025...
|
PUT Option | 0.00% | 0.26% |
Sold All 😨
(Was: #30) |
0.3 | -87,700 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-25 of 42 holdings